BioNote Past Earnings Performance
Past criteria checks 1/6
BioNote's earnings have been declining at an average annual rate of -44.6%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been declining at an average rate of 75.1% per year. BioNote's return on equity is 5.1%, and it has net margins of 85.9%.
Key information
-44.6%
Earnings growth rate
-44.8%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -75.1% |
| Return on equity | 5.1% |
| Net Margin | 85.9% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How BioNote makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 95,081 | 81,651 | 17,067 | 13,121 |
| 31 Mar 24 | 94,216 | 19,173 | 18,980 | 13,064 |
| 31 Dec 23 | 90,081 | -20,497 | 20,070 | 13,405 |
| 30 Sep 23 | 91,102 | -155,974 | 11,283 | 15,563 |
| 30 Jun 23 | 131,976 | -68,973 | 16,431 | 15,967 |
| 31 Mar 23 | 224,641 | 35,725 | 29,411 | 17,548 |
| 31 Dec 22 | 479,657 | 307,798 | 27,924 | 16,138 |
| 30 Sep 22 | 546,841 | 469,707 | 42,629 | 16,081 |
| 30 Jun 22 | 566,953 | 502,089 | 46,515 | 15,936 |
| 31 Mar 22 | 590,269 | 629,114 | 33,596 | 11,966 |
| 31 Dec 21 | 622,355 | 676,601 | 31,167 | 11,300 |
| 30 Sep 21 | 899,163 | 958,542 | 27,440 | 8,387 |
| 30 Jun 21 | 999,399 | 940,214 | 22,791 | 5,299 |
| 31 Mar 21 | 928,550 | 822,634 | 16,222 | 6,164 |
| 31 Dec 20 | 631,505 | 528,229 | 13,572 | 7,612 |
| 31 Dec 19 | 40,047 | 20,613 | 4,871 | 3,628 |
Quality Earnings: A377740 has a large one-off loss of ₩30.9B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: A377740 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A377740's earnings have declined by 44.6% per year over the past 5 years.
Accelerating Growth: A377740 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A377740 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A377740's Return on Equity (5.1%) is considered low.